| Literature DB >> 23343513 |
Abstract
This review article focuses on the anti-herpesvirus agents effective against herpes simplex virus, varicella-zoster virus and cytomegalovirus, which have either been licensed for clinical use (idoxuridine, trifluridine, brivudin, acyclovir, valaciclovir, valganciclovir, famciclovir and foscarnet) or are under clinical development (CMX001 [the hexadecyloxypropyl prodrug of cidofovir], the helicase-primase inhibitor BAY 57-1293 [now referred to as AIC316], FV-100 [the valine ester of Cf 1743] and the terminase inhibitor letermovir [AIC246]).Entities:
Mesh:
Substances:
Year: 2013 PMID: 23343513 DOI: 10.3851/IMP2533
Source DB: PubMed Journal: Antivir Chem Chemother ISSN: 0956-3202